Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is a targeted treatment for (CLL), approved by the U.S. Food & Drug Administration for both relapsed and newly diagnosed disease. Pivotal clinical trials found that ibrutinib shows favorable efficacy and is well tolerated in newly diagnosed patients, with about 9% discontinuing use after a year.
“The discovery points to the need for innovative approaches for novel treatments for the disease,” said Scott Huntington, M.D., M.P.H., assistant professor of medicine at YCC and lead author of the study. “Although ibrutinib is increasingly used in initial treatment of CLL in this country, patients are more likely to stop taking the drug than was reported in the pivotal trials.”
The researchers conducted a retrospective cohort study of CLL patients treated at community clinics using the nationwide Flatiron Health database. They found that use of ibrutinib for first-line (initial) treatment for the disease climbed to about 40% of patients by late 2018. Among about 1,500 of these individuals who received adequate follow-up, about 16% stopped taking ibrutinib within 180 days of initiation. This early discontinuation was especially common among people 80 years or older and among those whose disease had already progressed enough that they could not perform any work. The researchers noted that optimal strategies to manage ibrutinib-related toxicities are not well defined and suggested that clinical decision support tools and other modern cancer care delivery approaches should be explored to improve administration of novel CLL therapies.
About Yale Cancer Center and Smilow Cancer Hospital
Yale Cancer Center (YCC) is one of only 51 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 14 Smilow Cancer Hospital Care Centers in Connecticut. Smilow Cancer Hospital is accredited by the Commission on Cancer, a Quality program of the American College of Surgeons. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment
# # #
Original post https://alertarticles.info